Drug Trial Radar · NCT05322590
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
195
Planned (sponsor's estimate)
Start
Jan 9, 2023
Primary completion
Nov 2026
Study completion Apr 2029
Sponsor
- Lead sponsor
- Bexion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ICON plc; CTI Clinical Trial and Consulting Services
- First posted
- Apr 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7. All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be open label and will enroll participants at increasing dose levels of BXQ-350 in order to determine the Stage 2 dose. Stage 2 will be blinded; participants will receive BXQ-350 at the established Stage 1 dose or placebo.
Conditions
- Metastatic Colorectal Carcinoma
- Neuropathy
Interventions
BXQ-350Drug
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.
PlaceboOther
Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 DoseTime frame: 6 months
- Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0Time frame: 6 months
- Objective Response Rate (ORR)Time frame: 6 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
UC Irvine Health
Orange, California
Pacific Hematology Oncology Associates
San Francisco, California
Sylvester Comprehensive Cancer Center, University of Miami Hospitals and Clinics
Miami, Florida
The University of Iowa Hospitals and Clinics
Iowa City, Iowa
St. Elizabeth Healthcare
Edgewood, Kentucky
University of Kentucky/Markey Cancer Center
Lexington, Kentucky
University of Louisville, James Graham Brown Cancer Center
Louisville, Kentucky
University Medical Center New Orleans
New Orleans, Louisiana
Stony Brook Cancer Center
Stony Brook, New York
Gabrail Cancer Center Research
Canton, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.